secwatch.observer — SEC 8-K summary
======================================

Issuer:     LianBio (LIANY)
CIK:        0001831283
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001831283-22-000071
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LianBio Q3 net loss $21.9M; cash $331.8M; mavacamten Phase 3 data expected mid-2023
--------------------------------------------------------------------------------

- Net loss of $21.9M for Q3 2022 vs $13.1M YoY; R&D expenses $8.3M, G&A $16.3M.
- Cash, cash equivalents, securities $331.8M at Sep 30, 2022, down from $403.2M Dec 31, 2021; runway into 2H 2024.
- Mavacamten Phase 3 EXPLORER-CN data expected mid-2023; NDA submitted in Hong Kong; included in Chinese HCM guidelines.
- TP-03 Phase 3 LIBRA trial for Demodex blepharitis initiated in China; data expected Q4 2023; US NDA accepted, PDUFA Aug 25, 2023.
- Phase 3 NANORAY-312 (NBTXR3) for head & neck cancer initiated in Asia; Phase 1 BBP-398 dosing begun.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831283/000183128322000071/0001831283-22-000071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831283/000183128322000071/lian-20221110.htm
  HTML page:      https://secwatch.observer/filing/0001831283-22-000071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer